EVALUATION DE L’EFFICACITE THERAPEUTIQUE ET DE LA TOLERENCE DU TICAGRELOR CHEZ LES PATIENTS ATTEINTS DE SYNDROME CORONARIEN AIGU DANS LE SERVICE DE CARDIOLOGIE.

Abstract

Acute coronary syndrome (ACS) is a major cause of cardiovascular morbidity and mortality worldwide. Ticagrelor, a direct and reversible P2Y12 receptor antagonist, plays an important role in the antithrombotic management of patients with ACS. The objective of this study was to evaluate the therapeutic efficacy and tolerability of ticagrelor in real-world clinical practice at the Sétif University Hospital. A prospective observational study was conducted in the cardiology department of the Sétif University Hospital on a sample of 30 patients with ACS treated with ticagrelor. Demographic, clinical, and follow-up data were collected and analyzed to evaluate treatment outcomes and adverse effects. The analysis revealed a predominance of male patients (86.7%) with a mean age of 55.7 years. Cardiovascular risk factors were common, particularly diabetes, which was present in 56.7% of patients. The clinical results demonstrated satisfactory treatment efficacy with a low incidence of major adverse cardiovascular events (MACE), characterized by 6.7% ischemic recurrences and 6.7% cardiovascular deaths, with no rehospitalizations during the follow-up period. Regarding tolerability, major bleeding complications remained limited to 3.3%. However, dyspnea was the most common adverse effect, affecting 23.3% of patients and contributing to a treatment discontinuation rate due to intolerance of 16.7%. In conclusion, the results of this study suggest that ticagrelor is an effective and generally well-tolerated treatment option for patients with ACS in real-world clinical practice, despite the occurrence of certain adverse events requiring appropriate monitoring.